Leerink Partnrs Issues Negative Estimate for REGN Earnings

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) - Analysts at Leerink Partnrs decreased their Q2 2025 earnings per share (EPS) estimates for shares of Regeneron Pharmaceuticals in a research report issued on Monday, July 7th. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceutical company will post earnings per share of $6.97 for the quarter, down from their prior estimate of $7.71. The consensus estimate for Regeneron Pharmaceuticals' current full-year earnings is $35.92 per share.

A number of other research analysts have also recently issued reports on the company. Truist Financial lowered their price objective on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. Morgan Stanley lowered their price objective on Regeneron Pharmaceuticals from $958.00 to $755.00 and set an "overweight" rating for the company in a research note on Monday, June 2nd. Citigroup decreased their price target on Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating for the company in a research note on Monday, June 2nd. Cantor Fitzgerald assumed coverage on Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 price target for the company. Finally, Wells Fargo & Company cut Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and decreased their price target for the stock from $700.00 to $580.00 in a research note on Friday, May 30th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $822.58.

Regeneron Pharmaceuticals Stock Up 0.9%

NASDAQ:REGN traded up $4.83 during trading hours on Wednesday, reaching $552.58. 843,779 shares of the company traded hands, compared to its average volume of 909,261. The business's 50-day moving average price is $547.51 and its two-hundred day moving average price is $623.07. The stock has a market capitalization of $59.66 billion, a P/E ratio of 14.07, a P/E/G ratio of 1.98 and a beta of 0.33. Regeneron Pharmaceuticals has a 1 year low of $476.49 and a 1 year high of $1,211.20. The company has a current ratio of 4.93, a quick ratio of 4.03 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The company had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The firm's quarterly revenue was down 3.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $9.55 EPS.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.64%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.96%.

Institutional Trading of Regeneron Pharmaceuticals

Several institutional investors have recently made changes to their positions in the business. Gilman Hill Asset Management LLC grew its position in shares of Regeneron Pharmaceuticals by 2.1% during the second quarter. Gilman Hill Asset Management LLC now owns 5,415 shares of the biopharmaceutical company's stock worth $2,843,000 after purchasing an additional 112 shares in the last quarter. DLK Investment Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth about $402,000. Balefire LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth about $201,000. Triumph Capital Management grew its position in shares of Regeneron Pharmaceuticals by 42.4% during the second quarter. Triumph Capital Management now owns 843 shares of the biopharmaceutical company's stock worth $443,000 after purchasing an additional 251 shares in the last quarter. Finally, Woodstock Corp grew its position in shares of Regeneron Pharmaceuticals by 12.7% during the second quarter. Woodstock Corp now owns 8,021 shares of the biopharmaceutical company's stock worth $4,211,000 after purchasing an additional 906 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.